Novo Nordisk said it’s open to discussions with PBMs based on their commitments that a lower semgalutide list price would not impact formulary coverage.
Lauren Biscaldi
Advertisement
Articles by Lauren Biscaldi
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Optimal Physical Activity for Preventing Digestive System Cancers
2
Tubeless AID Systems Boost HRQoL in Type 1 Diabetes
3
Navigating Female Sexuality in Midlife Requires Provider Nuance and Patient Advocacy
4
Current Guideline Definitions of Barrett’s Esophagus May Fall Short in Detecting Esophageal Cancers
5
